ASLAN Pharmaceuticals Pte Ltd Reports Positive Results for Gastric Cancer Treatment
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
by Richard Daverman, PhD
Help employers find you! Check out all the jobs and post your resume.
by Richard Daverman, PhD
May 28, 2013 -- Aslan Pharmaceuticals Pte reported that ASLAN001 was effective in a Phase II trial among heavily pre-treated gastric cancer patients. ASLAN001, a small-molecule pan-HER inhibitor, reduced cell proliferation and cell survival in gastric tumors that either coexpressed EGFR and HER2 or were HER2 amplified. Aslan, a Singapore based biopharma that in-licenses clinicial-stage assets, acquired global rights to the drug from Array BioPharma in 2011. More details....
Stock Symbol: (NSDQ: ARRY)
Help employers find you! Check out all the jobs and post your resume.